Pfizer Asks High Court To Scrap Novartis Hemophilia Patents

Law360, New York (March 1, 2012, 2:18 PM EST) -- A Pfizer Inc. unit on Tuesday asked the U.S. Supreme Court to consider its argument that the Federal Circuit had erred in upholding Novartis Vaccines & Diagnostics Inc.'s hemophilia drug patents based on a related but later invention.

Genetics Institute LLC said in its petition for certiorari that the lower appeals court had incorrectly determined that Novartis' two protein patents were nonobvious and therefore valid based on the court's erroneous supposition that the patents posed a unique relationship with a later discovery that Novartis had not...
To view the full article, register now.